37th ACS National Medicinal Chemistry Symposium

American Chemical Society
Division of Medicinal Chemistry

 New York City, NY, United States    June 26-29, 2022

Session 1: Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery

Translating RNA Sequence into Lead Small Molecule Medicines

Prof. Matthew DISNEY
Prof. Matthew DISNEY
SCRIPPS RESEARCH INSTITUTE, Jupiter, United States
Read more

Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets

Prof. Kyle HADDEN
Prof. Kyle HADDEN
UNIVERSITY OF CONNECTICUT, Storrs, United States
Read more

Integrating DNA-Encoded Library Technologies in Lead Discovery

Dr Lisa MARCAURELLE
Dr Lisa MARCAURELLE
GSK, Cambridge, United States
Read more

Oral Peptides: Theory and Practice

Dr Lauren MONOVICH
Dr Lauren MONOVICH
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States
Read more

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiD Substrates for Oncology

Dr Lewis PENNINGTON
Dr Lewis PENNINGTON
KYMERA THERAPEUTICS INC., Watertown, United States
Read more

Session 2: New Directions in Targeting DNA Damage Repair (DDR)

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/cyclin T1 for MYC-dependent Cancers

Dr David  FREEMAN
Dr David FREEMAN
KRONOS BIO, INC. , Massachussetts, United States
Read more

M3541 and M4076: Discovery and Optimization of Potent and Selective ATM Kinase Inhibitors with Strong Anti-tumor Efficacy in Combination Therapies

Dr Thomas FUCHSS
Dr Thomas FUCHSS
MERCK KGAA, HEALTHCARE, Darmstadt, Germany
Read more

Discovery of human DNA Polymerase theta (Polθ) Inhibitors

Dr Robert HEALD
Dr Robert HEALD
ARTIOS PHARMA LTD, Cambridge, United Kingdom
Read more

Harnessing CDK12 Inhibition of Transcriptional Machinery to Induce Dimerization between DDB1 and CDK12-cyclinK Complex for Targeted Protein Degradation

Prof. Andrii MONASTYRSKYI
Prof. Andrii MONASTYRSKYI
MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Tampa, United States
Read more

The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response

Prof. Phil REIGAN
Prof. Phil REIGAN
UNIVERSITY OF COLORADO, Aurora, United States
Read more

Session 3: Hot Targets from NYC Academic and Biotech Scene

Designing and Combining Cancer's Off Switches

Dr Karen AKINSANYA
Dr Karen AKINSANYA
SCHRODINGER, New York City, United States
Read more

Rational Design of Inhibitors of Protein-Protein Interactions

Prof. Paramjit ARORA
Prof. Paramjit ARORA
NYU, New York, United States
Read more

Next Generation Drug Discovery

Dr Steve COLLETTI
Dr Steve COLLETTI
ZYMERGEN INC., New York, United States
Read more

Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd)

Dr John GINN
Dr John GINN
TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, United States
Read more

Therapeutic Potential of the Gut-Brain Axis

Dr Iyassu SEBHAT
Dr Iyassu SEBHAT
KALLYOPE, New Jersey, United States
Read more

Session 4: Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease

Chasing Challenging Targets: Development of Selective Inhibitors of the Autophagy Pathway to Impact Cancer Therapy

Prof. Leslie ALDRICH
Prof. Leslie ALDRICH
UNIVERISTY OF ILLINOIS AT CHICAGO, Chicago, United States
Read more

Revolutionizing Discovery and Development of ALS Therapeutics using Transformational, AI-powered 'All-in-Human' Platforms

Dr Irene CHOI
Dr Irene CHOI
VERGE GENOMICS, South San Francisco, United States
Read more

Necessary Complexity: The Discovery of Selective, CNS Penetrant LRRK2 Inhibitors for the Treatment of Parkinson’s Disease

Dr Peter FULLER
Dr Peter FULLER
MERCK & CO. INC., Boston, United States

Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration

Prof. Evripidis GAVATHIOTIS
Prof. Evripidis GAVATHIOTIS
ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States
Read more

Activating Mitophagy by targeting PTEN-Induced Kinase 1 (PINK1) for Parkinson's Disease

Dr Nicholas HERTZ
Dr Nicholas HERTZ
MITOKININ INC, San Francisco, United States
Read more

Unraveling Autophagy in Cancer Using Chemical Genetics

Prof. Jeff MACKEIGAN
Prof. Jeff MACKEIGAN
MICHIGAN STATE UNIVERSITY, East Lansing, United States
Read more

Session 5: Next Generation Therapies Shaped by Clinical Data

Discovery of Inavolisib, a Highly Selective Inhibitor of PI3K-α that Induces Degradation of Mutant-p110α Protein

Dr Marie-Gabrielle BRAUN
Dr Marie-Gabrielle BRAUN
GENENTECH, San Francisco, United States
Read more

Discovery of LPA1 antagonists for the treatment of Pulmonary Fibrotic Diseases

Dr Peter CHENG
Dr Peter CHENG
BRISTOL-MYERS SQUIBB R & D, Hopewell, United States
Read more

Discovery of Risdiplam, a Medicine for the Treatment of Spinal Muscular Atrophy

Dr Luke GREEN
Dr Luke GREEN
HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

Discovery of PF-07081532: a Small Molecule GLP-1 Receptor Agonist Suitable for Once-daily Oral Administration

Dr David GRIFFITH
Dr David GRIFFITH
PFIZER INC., Cambridge, United States
Read more

Discovery of LY3154885, a Second Generation Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile

Dr Erik HEMBRE
Dr Erik HEMBRE
ELI LILLY & CO., Indianapolis, United States
Read more

The Invention of MK-8262, a CETP Inhibitor for the Treatment of Coronary Heart Disease

Dr Petr VACHAL
Dr Petr VACHAL
MERCK & CO. INC (MSD), Kenilworth, United States
Read more

Session 6: Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry

Discovery of Nix-TB as a Novel Regimen that Significantly Shortens Treatment of Tuberculosis

Dr Christopher B. COOPER
Dr Christopher B. COOPER
TB ALLIANCE, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, New York, United States
Read more

Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor

Dr Kristine E. FRANK
Dr Kristine E. FRANK
ABBVIE, North Chicago, United States
Read more

Anticancer Drug Discovery from Pets to People, the Story of PAC-1

Prof. Paul J.  HERGENROTHER
Prof. Paul J. HERGENROTHER
UNIVERSITY OF ILLINOIS, Urbana, United States
Read more

From Concept to Clinic: the Story of M1 and mGlu4 Positive Allosteric Modulators (PAMs)

Prof. Craig LINDSLEY
Prof. Craig LINDSLEY
VANDERBILT UNIVERSITY, Nashville, United States
Read more

Drug Discovery: Where are We Headed?

Dr Wendy YOUNG
Dr Wendy YOUNG
MPM CAPITAL, Brisbane, CA, United States
Read more

Award Session

2022 Division of Medicinal Chemistry Award Lecture
A Perspective on the Arc of Innovation in Drug Discovery over Three Decades

Dr Lawrence G. HAMANN
Dr Lawrence G. HAMANN
STEALTH NEWCO, San Francisco, United States
Read more

2022 IUPAC-Richter Prize Lecture
Drug Discovery in Academia: Succesful Case Studies

Prof. Michael E. JUNG
Prof. Michael E. JUNG
UCLA CHEMISTRY & BIOCHEMISTRY, Los Angeles, United States
Read more